Literature DB >> 27111048

Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.

A K Singh1, L F Porrata2, O Aljitawi1, T Lin1, L Shune1, S Ganguly1, J P McGuirk1, S Abhyankar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27111048     DOI： 10.1038/bmt.2016.111

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  17 in total

Review 1.  The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

Authors:  Donatella Aldinucci; Annunziata Gloghini; Antonio Pinto; Rosaria De Filippi; Antonino Carbone
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

2.  Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Authors:  Philippe Armand; Arnon Nagler; Edie A Weller; Steven M Devine; David E Avigan; Yi-Bin Chen; Mark S Kaminski; H Kent Holland; Jane N Winter; James R Mason; Joseph W Fay; David A Rizzieri; Chitra M Hosing; Edward D Ball; Joseph P Uberti; Hillard M Lazarus; Markus Y Mapara; Stephanie A Gregory; John M Timmerman; David Andorsky; Reuven Or; Edmund K Waller; Rinat Rotem-Yehudar; Leo I Gordon
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Authors:  L Angenendt; C Schliemann; M Lutz; E Rebber; A B Schulze; M Weckesser; L Stegger; M Schäfers; C Groth; T Kessler; G Lenz; M Stelljes; W E Berdel
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

Review 5.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

7.  B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.

Authors:  Ruishu Deng; Kaniel Cassady; Xiaofan Li; Sheng Yao; Mingfeng Zhang; Jeremy Racine; Jeffrey Lin; Lieping Chen; Defu Zeng
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

8.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

9.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

Review 10.  Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Authors:  Brian T Fife; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988
View more
  33 in total

1.  Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  Mitra Bhattacharyya; Pablo Penaloza-MacMaster
Journal:  AIDS Res Hum Retroviruses       Date:  2018-04-18       Impact factor: 2.205

Review 2.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

Review 3.  Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.

Authors:  Reid W Merryman; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 4.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

5.  MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD.

Authors:  A-M Boekstegers; F Blaeschke; I Schmid; V Wiebking; S Immler; F Hoffmann; K Bochmann; S Müller; T G P Grünewald; J Feucht; T Feuchtinger
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

6.  Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.

Authors:  F-X Gros; T Cazaubiel; E Forcade; N Lechevalier; T Leguay; V Servant; R Tabrizi; L Clement; P-Y Dumas; A Bidet; A Pigneux; S Vigouroux; N Milpied
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

7.  PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Authors:  J C Albring; S Inselmann; T Sauer; C Schliemann; B Altvater; S Kailayangiri; C Rössig; W Hartmann; J R Knorrenschild; K Sohlbach; C Groth; M Lohoff; A Neubauer; W E Berdel; A Burchert; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

Review 8.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Authors:  Awais Ijaz; Ali Younas Khan; Saad Ullah Malik; Warda Faridi; Muhammad Asad Fraz; Muhammad Usman; Muhammad Junaid Tariq; Seren Durer; Ceren Durer; Atlantis Russ; Nadia Nunes Cavalcante Parr; Zeeshan Baig; Fnu Sagar; Zeeshan Ali; Ali McBride; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-06       Impact factor: 5.742

9.  Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Authors:  Makoto Onizuka; Minoru Kojima; Keiko Matsui; Shinichiro Machida; Masako Toyosaki; Yasuyuki Aoyama; Hidetsugu Kawai; Jun Amaki; Ryujiro Hara; Akifumi Ichiki; Yoshiaki Ogawa; Hiroshi Kawada; Naoya Nakamura; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2017-01-17       Impact factor: 2.490

10.  The Potentials and Pitfalls of Using Adult Stem Cells in Cancer Treatment.

Authors:  Mrinal K Das; Taral R Lunavat; Hrvoje Miletic; Jubayer A Hossain
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.